FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

felzartamab

Drug and asset intelligence for felzartamab with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 2
Stage: Development stage unavailable

Sponsor company

Biogen →

Recent signals(2)

ClinicalJuly 6, 2026

Biogen's Felzartamab Study Targets Isolated Microvascular Inflammation in Kidney Transplant Patients

A study is underway to evaluate the effects of felzartamab on isolated microvascular inflammation in kidney transplant recipients.

ClinicalJune 18, 2026

Biogen's Felzartamab Study Targets Immunoglobulin A Nephropathy in Adults

A clinical trial is underway to evaluate the effects of felzartamab on proteinuria in adults with IgAN.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Biogen — felzartamab

July 6, 2026 · N/A

Topline Data

Biogen — Felzartamab

June 18, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Kidney Transplant →

Nephrology →

Nephrology · Kidney Transplant →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.